🎉 M&A multiples are live!
Check it out!

Sanofi Valuation Multiples

Discover revenue and EBITDA valuation multiples for Sanofi and similar public comparables like Armata Pharmaceuticals, Vivoryon Therapeutics, and Pharming.

Sanofi Overview

About Sanofi

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.


Founded

1994

HQ

France
Employees

82.9K+

Website

sanofi.com

Financials

LTM Revenue $49.0B

LTM EBITDA $14.3B

EV

$156B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Sanofi Financials

Sanofi has a last 12-month revenue of $49.0B and a last 12-month EBITDA of $14.3B.

In the most recent fiscal year, Sanofi achieved revenue of $48.4B and an EBITDA of $12.0B.

Sanofi expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Sanofi valuation multiples based on analyst estimates

Sanofi P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $50.7B $48.4B XXX XXX XXX
Gross Profit $34.6B $35.2B XXX XXX XXX
Gross Margin 68% 73% XXX XXX XXX
EBITDA $13.8B $12.0B XXX XXX XXX
EBITDA Margin 27% 25% XXX XXX XXX
Net Profit $9.1B $5.9B XXX XXX XXX
Net Margin 18% 12% XXX XXX XXX
Net Debt $6.9B $8.4B XXX XXX XXX

Financial data powered by Morningstar, Inc.

Sanofi Stock Performance

As of March 14, 2025, Sanofi's stock price is EUR 106 (or $116).

Sanofi has current market cap of EUR 133B (or $145B), and EV of EUR 143B (or $156B).

See Sanofi trading valuation data

Sanofi Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$156B $145B XXX XXX XXX XXX $8.05

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Sanofi Valuation Multiples

As of March 14, 2025, Sanofi has market cap of $145B and EV of $156B.

Sanofi's trades at 3.2x LTM EV/Revenue multiple, and 11.0x LTM EBITDA.

Analysts estimate Sanofi's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Sanofi and 10K+ public comps

Sanofi Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $156B XXX XXX XXX
EV/Revenue 3.2x XXX XXX XXX
EV/EBITDA 13.0x XXX XXX XXX
P/E 23.9x XXX XXX XXX
P/E/Growth 0.6x XXX XXX XXX
EV/FCF 24.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Sanofi Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Sanofi Valuation Multiples

Sanofi's NTM/LTM revenue growth is 7%

Sanofi's revenue per employee for the last fiscal year averaged $0.6M, while opex per employee averaged $0.3M for the same period.

Over next 12 months, Sanofi's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Sanofi's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Sanofi and other 10K+ public comps

Sanofi Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -5% XXX XXX XXX XXX
EBITDA Margin 25% XXX XXX XXX XXX
EBITDA Growth -12% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 31% XXX XXX XXX XXX
Revenue per Employee $0.6M XXX XXX XXX XXX
Opex per Employee $0.3M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 17% XXX XXX XXX XXX
Opex to Revenue 49% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Sanofi Public Comps

See public comps and valuation multiples for Biopharmaceuticals and Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
Armata Pharmaceuticals XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Sanofi M&A and Investment Activity

Sanofi acquired  XXX companies to date.

Last acquisition by Sanofi was  XXXXXXXX, XXXXX XXXXX XXXXXX . Sanofi acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Sanofi

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Sanofi

When was Sanofi founded? Sanofi was founded in 1994.
Where is Sanofi headquartered? Sanofi is headquartered in France.
How many employees does Sanofi have? As of today, Sanofi has 82.9K+ employees.
Who is the CEO of Sanofi? Sanofi's CEO is Mr. Paul Hudson.
Is Sanofi publicy listed? Yes, Sanofi is a public company listed on PAR.
What is the stock symbol of Sanofi? Sanofi trades under SAN ticker.
When did Sanofi go public? Sanofi went public in 1999.
Who are competitors of Sanofi? Similar companies to Sanofi include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics.
What is the current market cap of Sanofi? Sanofi's current market cap is $145B
What is the current revenue of Sanofi? Sanofi's last 12-month revenue is $49.0B.
What is the current EBITDA of Sanofi? Sanofi's last 12-month EBITDA is $14.3B.
What is the current EV/Revenue multiple of Sanofi? Current revenue multiple of Sanofi is 3.2x.
What is the current EV/EBITDA multiple of Sanofi? Current EBITDA multiple of Sanofi is 11.0x.
What is the current revenue growth of Sanofi? Sanofi revenue growth between 2023 and 2024 was -5%.
Is Sanofi profitable? Yes, Sanofi is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.